Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
Items 201–300 of 963
Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers
Soontornniyomkij, V., Moore, D. J., Gouaux, B. D., Soontornniyomkij, B., Tatro, E. T., Umlauf, A., Masliah, E., Levine, A. J., Singer, E. J., Vinters, H. V., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32835a117c · Cited by 106
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
Ikonomovic, M. D., Buckley, C. J., Heurling, K., Sherwin, P., Jones, P. A., Zanette, M., Mathis, C. A., Klunk, W. E., Chakrabarty, A., Ironside, J., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0399-z · Cited by 98
Self-citationBabiloni, C., Lizio, R., Del Percio, C., Marzano, N., Soricelli, A., Salvatore, E., Ferri, R., Cosentino, F. I. I., Tedeschi, G., Montella, P., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-121750 · Cited by 99
“Furthermore, PET-amyloid Pittsburg Compound (cid:1) deposition in the brain of AD patients [15–17].”
Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease
Canobbio, I., Abubaker, A. A., Visconte, C., Torti, M., & Pula, G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00065 · Cited by 112
Estrogen Regulation of Mitochondrial Bioenergetics
Yao, J., & Brinton, R. D. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-394816-8.00010-6 · Cited by 88
“Currently, the most thoroughly studied biomarkers of AD are the levels of three proteins measured in the cerebrospinal fluid (CSF): amyloid β1–42 (Aβ42), total tau protein, and p-tau, a phosphorylated form of tau protein.”
BackgroundInfluentialVillemagne, V. L., Furumoto, S., Fodero-Tavoletti, M., Harada, R., Mulligan, R. S., Kudo, Y., Masters, C. L., Yanai, K., Rowe, C. C., & Okamura, N. (2012) · Future Neurology · doi:10.2217/fnl.12.34 · Cited by 97
Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
(2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 99
“Strong direct correlations were also observed between antemortem DVR values and region matched postmortem biochemistry measures of total Aβ42 and Aβ40 concentration or [H-3]PiB binding in frozen tissue homogenates from this case.”
InfluentialSelf-citationBabiloni, C., Percio, C. D., Bordet, R., Bourriez, J., Bentivoglio, M., Payoux, P., Derambure, P., Dix, S. L., Infarinato, F., Lizio, R., et al. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.09.017 · Cited by 103
“, 1997); PET-amyloid Pittsburg Compound B (PIB) is also used for the visualisation of A beta amyloid deposition in the brain (Klunk et al., 2004; Rowe et al., 2007; Ikonomovic et al., 2008).”
High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease
Stukas, S. K., Robert, J., & Wellington, C. L. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.003 · Cited by 112
Rosen, R. F., Walker, L. C., & LeVine, H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.011 · Cited by 97
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“There is no affinity for cerebellar plaques and only partial affinity for extracellular ‘ghost tangles’, probably due to adjacent neuritic plaques (Ikonomovic et al., 2008).”
BackgroundInfluentialBiomarkers in dementia with Lewy bodies: a review
Sinha, N., Firbank, M., & O'Brien, J. T. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2749 · Cited by 101
“In vitro, PIB has been shown to bind specifically to extracellular and intravascular fibrillar Aβ deposits in post‐mortem AD brains (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundCohen, A. D., Mowrey, W., Weissfeld, L. A., Aizenstein, H. J., McDade, E., Mountz, J. M., Nebes, R. D., Saxton, J. A., Snitz, B., DeKosky, S., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.01.015 · Cited by 97
“Since the initial amyloid imaging studies using PiB (Klunk et al., 2004), it has become widely accepted that this technique provides a quantitative representation of fibrillar Aβ deposition in the brain (Ikonomovic et al., 2008).”
BackgroundSelf-citationSeshadri, S., Beiser, A., Au, R., Wolf, P. A., Evans, D. A., Wilson, R. S., Petersen, R. C., Knopman, D. S., Rocca, W. A., Kawas, C. H., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.002 · Cited by 97
“More recent studies using molecular imaging techniques such as amyloid imaging will shed light on issues concerning the prevalence or at least the frequency of the amyloid substrate (abnormal amyloid deposition) in persons with and without clinical symptoms [49–51].”
BackgroundIn vivo mapping of amyloid toxicity in Alzheimer disease
Frisoni, G. B., Lorenzi, M., Caroli, A., Kemppainen, N., Någren, K., & Rinne, J. O. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e896 · Cited by 96
A Review of Imaging Agent Development
Agdeppa, E. D., & Spilker, M. E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9104-5 · Cited by 115
Detection of isolated cerebrovascular β‐amyloid with pittsburgh compound B
Greenberg, S. M., Grabowski, T., Gurol, M. E., Skehan, M. E., Nandigam, R. N. K., Becker, J. A., Garcia‐Alloza, M., Prada, C., Frosch, M. P., Rosand, J., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21528 · Cited by 96
Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease
Cha, M.-Y., Cho, H. J., Kim, C., Jung, Y. O., Kang, M. J., Murray, M. E., Hong, H. S., Choi, Y.-J., Choi, H., Kim, D. K., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv358 · Cited by 100
Positron Emission Tomography Radiopharmaceuticals for Imaging Brain Beta-Amyloid
Vallabhajosula, S. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.02.005 · Cited by 104
Professional Fighters Brain Health Study: Rationale and Methods
Bernick, C. B., Banks, S. J., Phillips, M., Lowe, M. J., Shin, W., Obuchowski, N. A., Jones, S., & Modic, M. T. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws456 · Cited by 98
Neurodegeneration in Diabetes Mellitus
Umegaki, H. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0653-2_19 · Cited by 109
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
“Both techniques are presumed to measure brain Aβ amyloid load [8-14] (referred to from here on as Aβ load) which is an important disease feature that must be ascertained in individual subjects for many therapeutic and observational studies.”
BackgroundDoré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93
Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults
Meyer, P., Ashton, N. J., Karikari, T. K., Strikwerda‐Brown, C., Köbe, T., Gonneaud, J., Pichet Binette, A., Ozlen, H., Yakoub, Y., Simrén, J., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26308 · Cited by 91
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation
Klunk, W. E., & Mathis, C. A. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283168e1a · Cited by 92
Self-citationGeneral anesthetic and the risk of dementia in elderly patients: current insights
Seitz, D. P., Hussain, M., Eckenhoff, R. G., & Berger, M. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s49680 · Cited by 107
Amyloid imaging in Alzheimer's disease
Nordberg, A. K. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.03.020 · Cited by 98
Retinal Vasculopathy in Alzheimer’s Disease
Shi, H., Koronyo, Y., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Mirzaei, N., & Koronyo‐Hamaoui, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.731614 · Cited by 91
Amyloid Deposition Is Linked to Aberrant Entorhinal Activity among Cognitively Normal Older Adults
Huijbers, W., Mormino, E. C., Wigman, S. E., Ward, A. M., Vannini, P., McLaren, D. G., Becker, J. A., Schultz, A. P., Hedden, T., Johnson, K. A., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3579-13.2014 · Cited by 89
“Based on the consistency between PET amyloid imaging and postmortem counts of plaques and tangles, it is likely that many A older adults also harbor tau in entorhinal cortex (Braak and Braak, 1991; Ikonomovic et al., 2008; Sperling et al., 2011).”
BackgroundQuantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Lowe, V. J., Lundt, E. S., Albertson, S. M., Przybelski, S. A., Senjem, M. L., Parisi, J. E., Kantarci, K., Boeve, B., Jones, D. T., Knopman, D., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.016 · Cited by 90
“The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) score is a semiquantitative assessment of neuritic plaques [13], which has been shown to correlate with a range of fibrillar Ab deposits that should have signal on amyloid-PET as suggested by early pathologic correlation [14,15].”
BackgroundAmyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy
Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90
Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome
Neale, N., Padilla, C., Fonseca, L. M., Holland, T., & Zaman, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.10.022 · Cited by 86
“…the current amyloid ligands available are useful tools for detecting AD, one drawback is their limited ability to detect non-neuritic amyloid plaques that may occur in a prodromal or early stage of dementia (Cairns et al., 2009; Ikonomovic et al., 2008; Iwatsubo et al., 1995; Lemere et al., 1996).”
BackgroundNeuropsychiatric symptoms in the prodromal stages of dementia
Stella, F., Radanovic, M., Balthazar, M. L. F., Canineu, P. R., de Souza, L. C., & Forlenza, O. V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000050 · Cited by 90
Kwan, A. C., Duff, K., Gouras, G. K., & Webb, W. W. (2009) · Optics Express · doi:10.1364/oe.17.003679 · Cited by 95
“Positron emission tomography (PET) imaging of Pittsburgh Compound-B has been shown to bind amyloid-beta deposits in human patients in vivo [1].”
BackgroundSalivary Biomarkers for Alzheimer’s Disease and Related Disorders
Ashton, N. J., Ide, M., Zetterberg, H., & Blennow, K. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00168-1 · Cited by 89
Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan
Fouquet, M., Besson, F. L., Gonneaud, J., Joie, R. L., & Chételat, G. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9263-8 · Cited by 95
“…Assessed with PET Aβ load as assessed using PET with Aβ ligands (PiB, florbetapir, florbetaben, flutemetamol) has been consistently shown to correlate with neuropathological measures of Aβ deposition (Bacskai et al. 2007; Ikonomovic et al. 2008; Leinonen et al. 2008; Clark et al. 2011; 2012).”
MethodToledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
“There are several non– mutually exclusive explanations for this finding: (1) the changes are small and might not be detected owing to the inherent variability of the measurements, (2) a longer follow-up is needed to see larger changes, and (3) the different dynamic ranges of these 2 biomarkers could lead to different…”
Molecular imaging in dementia: Past, present, and future
Laforce, R., Soucy, J., Sellami, L., Dallaire‐Théroux, C., Brunet, F., Bergeron, D., Miller, B. L., & Ossenkoppele, R. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.2855 · Cited by 88
“[83] Ikonomovic M, Klunk W, Abrahamson E, Mathis C, Price J, Tsopelas N, et al.”
BackgroundSalloway, S., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.06.001 · Cited by 87
Ikonomovic, M. D., Abrahamson, E. E., Price, J. C., Hamilton, R. L., Mathis, C. A., Paljug, W. R., Debnath, M. L., Cohen, A. D., Mizukami, K., DeKosky, S. T., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0943-2 · Cited by 85
Self-citationAmyloid-β Positron Emission Tomography Imaging Probes: A Critical Review
Kepe, V., Moghbel, M. C., Långström, B., Zaidi, H., Vinters, H. V., Huang, S.-C., Satyamurthy, N., Doudet, D., Mishani, E., Cohen, R. M., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130485 · Cited by 86
Hu, N.-W., Smith, I. M., Walsh, D. M., & Rowan, M. J. (2008) · Brain · doi:10.1093/brain/awn174 · Cited by 84
“Alzheimer's disease is characterized pathologically by the deposition of insoluble aggregates of fibrillar amyloid-b protein (Ab) in neuritic plaques and blood vessels (termed cerebral amyloid angiopathy), and tau protein in neurofibrillary tangles (Ikonomovic et al., 2008).”
BackgroundMadeira, M. H., Boia, R., Ambrósio, A. F., & Santiago, A. R. (2017) · Mediators of Inflammation · doi:10.1155/2017/4761081 · Cited by 95
Quantitative imaging of protein targets in the human brain with PET
Gunn, R. N., Slifstein, M., Searle, G. E., & Price, J. C. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/22/r363 · Cited by 99
Self-citationUnbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N. (2012) · Human Brain Mapping · doi:10.1002/hbm.21386 · Cited by 84
Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis
Ruan, D., & Sun, L. (2023) · Brain and Behavior · doi:10.1002/brb3.2850 · Cited by 74
“A strong correlation between 11C-PIB retention in the brain and pathol- ogy (neuroinflammatory plaques and vascular amyloid) at autopsy has been reported early on (Ikonomovic et al., 2008).”
BackgroundSvedberg, M. M., Hall, H., Hellström‐Lindahl, E., Estrada, S., Guan, Z.-Z., Nordberg, A. K., & Långström, B. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.016 · Cited by 93
Knight, W. D., Okello, A. A., Ryan, N. S., Turkheimer, F. E., Rodríguez Martinez de Llano, S., Edison, P., Douglas, J., Fox, N. C., Brooks, D. J., & Rossor, M. N. (2011) · Brain · doi:10.1093/brain/awq310 · Cited by 84
Rinne, J. O., Wong, D. F., Wolk, D. A., Leinonen, V., Arnold, S. E., Buckley, C. J., Smith, A. P. L., McLain, R. W., Sherwin, P. F., Farrar, G., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1051-z · Cited by 91
An Overview of PET Neuroimaging
Nasrallah, I. M., & Dubroff, J. G. (2013) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2013.06.003 · Cited by 92
Eric E Hall, M. H. S. (2014) · Journal of Alzheimer's Disease & Parkinsonism · doi:10.4172/2161-0460.1000137 · Cited by 79
“Utilizing the PiB compound to map Aβ pathology via PET has been supported by strong correlations to post-mortem Aβ pathology findings [121].”
MethodTau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy
Lesman‐Segev, O. H., Joie, R. L., Stephens, M. L., Sonni, I., Tsai, R. M., Bourakova, V., Visani, A. V., Edwards, L., O’Neil, J. P., Baker, S. L., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.102025 · Cited by 90
Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease
Rosen, R. F., Ciliax, B. J., Wingo, T. S., Gearing, M., Dooyema, J., Lah, J. J., Ghiso, J. A., LeVine, H., & Walker, L. C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0583-3 · Cited by 82
“Evaluation of postmortem or biopsied brain samples from patients who exhibited cortical PIB retention in PET scans indicates that PIB binding in vivo correlates with heavy cerebral Ab deposition [2, 10 , 16].”
BackgroundResultInfluentialA systematic review and meta‐analysis of 18F‐labeled amyloid imaging in Alzheimer's disease
Yeo, J. M., Waddell, B., Khan, Z. H., & Pal, S. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.004 · Cited by 99
“Imaging using (11)C-PiB has been reported to successfully differentiate between patients with AD and healthy controls [4], predict the progression of mild cognitive impairment (MCI) to symptomatic AD [5], and correlate with underlying amyloid neuropathology [6].”
BackgroundPrecuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Wuu, J., Mathis, C. A., Scheff, S. W., Mufson, E. J., & DeKosky, S. T. (2011) · Neurology · doi:10.1212/wnl.0b013e3182231419 · Cited by 84
Self-citationRaji, C. A., Becker, J. T., Tsopelas, N. D., Price, J. C., Mathis, C. A., Saxton, J. A., Lopresti, B. J., Hoge, J. A., Ziolko, S. K., DeKosky, S. T., et al. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.05.005 · Cited by 83
“4 nM) and specificity to amyloid in AD brains (Mathis et al, 2003) (Ikonomovic et al. 2008), (Klunk et al.”
BackgroundSelf-citationPathology of clinical and preclinical Alzheimer’s disease
Thal, D. R., Arnim, C. A. F. V., Griffin, W. S. T., Yamaguchi, H., Mrak, R. E., Attems, J., & Upadhaya, A. R. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0449-5 · Cited by 85
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
Yu, Y., Sun, X., Tang, D., Li, C., Zhang, L., Nie, D., Yin, X., & Shi, G. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.12.041 · Cited by 85
Practical utility of amyloid and FDG-PET in an academic dementia center
Sánchez-Juan, P., Ghosh, P. M., Hagen, J., Gesierich, B., Henry, M., Grinberg, L. T., O'Neil, J. P., Janabi, M., Huang, E. J., Trojanowski, J. Q., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000032 · Cited by 78
Fodero-Tavoletti, M. T., Furumoto, S., Taylor, L., McLean, C. A., Mulligan, R. S., Birchall, I., Harada, R., Masters, C. L., Yanai, K., Kudo, Y., et al. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt240 · Cited by 73
“It is noteworthy that variable staining of NFTs at high concentrations of PiB has also been reported [52].”
BackgroundBabiloni, C., Percio, C. D., Lizio, R., Marzano, N., Infarinato, F., Soricelli, A., Salvatore, E., Ferri, R., Bonforte, C., Tedeschi, G., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.019 · Cited by 84
“, 2009); (2) deposition of A beta amyloid in the brain, revealed using PETamyloid Pittsburg compound-B (PIB; Ikonomovic et al., 2008; Rowe et al., 2007); (3) hypometabolism of the posterior cingulate, precuneus, parietal, and temporal regions revealed using PET-FDG (Jagust et al.”
Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 75
“This regional distribution visualised by Aβ PET retention closely follows the sequence of Aβ burden highlighted by post mortem studies [47-49].”
BackgroundIslam, T., Hill, E., Abrahamson, E. E., Servaes, S., Smirnov, D. S., Zeng, X., Sehrawat, A., Chen, Y., Kac, P. R., Kvartsberg, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03400-0 · Cited by 85
Self-citationAmyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
Prvulovic, D., & Hampel, H. (2011) · cclm · doi:10.1515/cclm.2011.087 · Cited by 73
“Post-mortem autopsy studies revealed good correlation between PiB binding and histological fibrillar Ab deposits (53, 55).”
Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease
Tolboom, N., Yaqub, M., Boellaard, R., Luurtsema, G., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1129-6 · Cited by 78
“Although these diffuse amyloid deposits in the cerebellum were not detectable in a 6-CN-PiB staining study [11], more data on cerebellar [(11)C]PIB binding in vivo are necessary.”
BackgroundDefining and labeling disease‐modifying treatments for Alzheimer's disease
Cummings, J. L. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.12.003 · Cited by 71
“PIB-PET shows the extent of deposition of fibrillary amyloid in the brain in diffuse and neuritic plaques [38].”
BackgroundChiotis, K., Saint‐Aubert, L., Boccardi, M., Gietl, A. F., Picco, A., Varrone, A., Garibotto, V., Herholz, K., Nobili, F. M., Nordberg, A. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.012 · Cited by 84
Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting
Plissonneau, M., Pansieri, J., Heinrich, L., Morfin, J., Stransky-Heilkron, N., Rivory, P., Mowat, P., Dumoulin, M., Cohen, R., Allémann, É., et al. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0212-y · Cited by 79
“Such picture could be correlated with compact/cored amyloid plaque [55] and diffuse plaques [53].”
BackgroundExploring new routes for neuroprotective drug development in traumatic brain injury
Janowitz, T., & Menon, D. K. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000330 · Cited by 74
Yu, Y., Zhang, L., Li, C., Sun, X., Tang, D., & Shi, G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201405001 · Cited by 78
Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex
Sepulcre, J., Grothe, M. J., Sabuncu, M., Chhatwal, J., Schultz, A. P., Hanseeuw, B., El Fakhri, G., Sperling, R., & Johnson, K. A. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0263 · Cited by 73
Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective
Lewczuk, P., Mroczko, B., Fagan, A. M., & Kornhuber, J. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.11.002 · Cited by 78
“fibrillar Ab in the brains of patients who had undergone PiB-PET imaging during life and post mortem neuropathologic examination [83], which means that PiB binds to fibrillar Ab, and not to soluble Ab.”
BackgroundKantarci, K., Lowe, V., Przybelski, S. A., Senjem, M. L., Weigand, S. D., Ivnik, R. J., Roberts, R., Geda, Y. E., Boeve, B. F., Knopman, D. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822dc7e1 · Cited by 71
Ma, Y., Zhang, S., Li, J., Zheng, D.-M., Guo, Y., Feng, J., & Ren, W.-D. (2014) · Medicine · doi:10.1097/md.0000000000000150 · Cited by 69
“To date, the most studied and validated PET marker of Ab aggregation is 11C-Pittsburgh compound B (11CPIB), which shows a nanomolar affinity for the extracellular and intravascular fibrillar deposits of Ab and a low affinity toward the amorphous amyloid deposits, soluble Ab, and intracellular NFTs.13 11C-PIB-PET imagi…”
BackgroundYousefi, B. H., Manook, A., Drzezga, A. E., von Reutern, B., Schwaiger, M., Wester, H., & Henriksen, G. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101129a · Cited by 78
Biological applications of near infrared fluorescence dye probes in monitoring Alzheimer's disease.
Gyasi, Y. I., Pang, Y., Li, X.-R., Gu, J.-X., Cheng, X.-J., Liu, J., Xu, T., & Liu, Y. (2019) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2019.111982 · Cited by 62
Formaglio, M., Costes, N., Seguin, J., Tholance, Y., Bars, D. L., Roullet‐Solignac, I., Mercier, B., Krolak‐Salmon, P., & Vighetto, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6030-0 · Cited by 74
“It correlates with the presence and the concentration of neuritic plaques characteristic of AD [ 18 ].”
BackgroundAnte mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies
Kantarci, K., Yang, C., Schneider, J. A., Senjem, M. L., Reyes, D. A., Lowe, V. J., Barnes, L. L., Aggarwal, N. T., Bennett, D. A., Smith, G. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.007 · Cited by 70
Cortical α7 Nicotinic Acetylcholine Receptor and β-Amyloid Levels in Early Alzheimer Disease
Ikonomovic, M. D., Wecker, L., Abrahamson, E. E., Wuu, J., Counts, S. E., Ginsberg, S. D., Mufson, E. J., & DeKosky, S. T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.46 · Cited by 71
Self-citationAmyloid PET imaging: applications beyond Alzheimer’s disease
Catafau, A. M., & Bullich, S. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0098-3 · Cited by 71
Beta‐amyloid protein (25–35) disrupts hippocampal network activity: Role of Fyn‐kinase
Peña, F., Ordaz, B., Balleza‐Tapia, H., Bernal‐Pedraza, R., Márquez‐Ramos, A., Carmona‐Aparicio, L., & Giordano, M. (2010) · Hippocampus · doi:10.1002/hipo.20592 · Cited by 72
Sugihara causality analysis of scalp EEG for detection of early Alzheimer's disease
McBride, J. C., Zhao, X., Munro, N. B., Jicha, G. A., Schmitt, F. A., Kryscio, R. J., Smith, C. D., & Jiang, Y. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.12.005 · Cited by 80
Marutle, A., Gillberg, P.-G., Bergfors, A., Yu, W., Ni, R., Nennesmo, I., Voytenko, L., & Nordberg, A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-90 · Cited by 70
“The detection of cerebral β-amyloidosis in vivo in patients with PET amyloid imaging tracers such as [(11)C]PIB have been shown to correlate well with levels of fibrillar Aβ measured in AD brain at autopsy [6,33].”
BackgroundPET molecular imaging for pathophysiological visualization in Alzheimer’s disease
Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 76
“Though 11CPIB was found bind to tau [113] and α-synuclein [114] as well, in the concentrations clinically used, neurofibrillary tangles [115] and Lewy bodies [114] do not contribute to the retention of PIB.”
BackgroundAuditory spatial processing in Alzheimer’s disease
Golden, H. L., Nicholas, J. M., Yong, K. X. X., Downey, L. E., Schott, J. M., Mummery, C. J., Crutch, S. J., & Warren, J. D. (2015) · Brain · doi:10.1093/brain/awu337 · Cited by 68
“In large case series, underlying Alzheimer’s disease pathology has been found in most patients presenting with PCA (Tang-Wai et al., 2004; Ikonomovic et al., 2008; Crutch et al., 2012).”
BackgroundNeuroimaging in Vascular Cognitive Impairment and Dementia: A Systematic Review
Frantellizzi, V., Pani, A., Ricci, M., Locuratolo, N., Fattapposta, F., & VINCENTIS, G. D. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191046 · Cited by 76
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 88
“Post-mortem studies demonstrated that, compared to controls, AD patients show elevated retention of PIB in cortical areas consistent with A β deposition patterns [19, 20].”
Zhao, Y., Raichle, M. E., Wen, J., Benzinger, T. L. S., Fagan, A. M., Hassenstab, J. J., Vlassenko, A. G., Luo, J., Cairns, N. J., Christensen, J. J., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.12.026 · Cited by 73
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 76
Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
van Westen, D., Lindqvist, D., Blennow, K., Minthon, L., Nägga, K., Stomrud, E., Zetterberg, H., & Hansson, O. (2016) · Scientific Reports · doi:10.1038/srep20709 · Cited by 66
Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study
Zwan, M. D., Rinne, J. O., Hasselbalch, S. G., Nordberg, A., Lleó, A., Herukka, S.-K., Soininen, H., Law, I., Bahl, J. M. C., Carter, S. F., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002081 · Cited by 66
Landt, J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.36 · Cited by 65
Update on amyloid imaging: From healthy aging to Alzheimer’s disease
Wolk, D. A., & Klunk, W. E. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0051-4 · Cited by 63
Self-citation11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease
Villemagne, V. L., McLean, C. A., Reardon, K., Boyd, A., Lewis, V, Klug, G., Jones, G., Baxendale, D., Masters, C. L., Rowe, C. C., et al. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.171496 · Cited by 67
“C-PiB retention and Aβ concentrations assessed at postmortem or brain biopsy.”
BackgroundThe Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging
Fantoni, E., Collij, L., Alves, I. L., Buckley, C., & Farrar, G. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235879 · Cited by 61
“by a predominance of amyloid plaques of diffuse form, to which amyloid tracers are less sensitive than they are to higher-density neuritic plaques (41,49).”
BackgroundClinical and research diagnostic criteria for Alzheimer's disease
Sarazin, M., de Souza, L. C., Lehéricy, S., & Dubois, B. (2012) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.004 · Cited by 64
“(11)C-PiB binds specifically to fibrillar b-amyloid (Ab) deposits, amyloid plaques, and vascular amyloid, but not appreciably to other protein aggregates such as NFTs or Lewy bodies.(47) (11)CPiB binds nonspecifically to white matter, likely because of delayed clearance of the lipophilic compound from white matter.”
BackgroundVandenberghe, R. R., Nelissen, N., Salmon, É., Ivanoiu, A., Hasselbalch, S. G., Andersen, A., Kørner, A., Minthon, L., Brooks, D. J., Laere, K. V., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.015 · Cited by 74
“…al., 2009; Nelissen et al., 2009; Vandenberghe et al., 2010) of 11 C-Pittsburgh Compound B (PIB) (Klunk et al., 2003, 2004; Lockhart et al., 2007; Ikonomovic et al., 2008), 27 patients with clinically probable AD, 25 healthy controls and 20 patients with amnestic mild cognitive impairment (MCI)…”
Influential
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.